Financial Data and Key Metrics Changes - Total operating expenses for Q1 2023 were $18.1 million, an increase of $2.1 million compared to Q1 2022, and $1.8 million above the previous quarter [49] - The net loss for Q1 2023 was $15.0 million, compared to $15.8 million in Q1 2022 [49] - Cash, cash equivalents, and investments at the end of the quarter were approximately $302 million, down from $314 million at the end of the previous year [13] Business Line Data and Key Metrics Changes - Research and development expenses for Q1 2023 were $10.9 million, compared to $9.7 million in Q1 2022 [49] - General and administrative expenses were $7.2 million in Q1 2023, compared to $6.4 million in Q1 2022 [49] Market Data and Key Metrics Changes - The current annual proteomics market is estimated to be approximately $27 billion, growing at a 15% CAGR [5] Company Strategy and Development Direction - The company aims to provide ubiquitous access to the proteome for labs, researchers, and clinicians globally, with a focus on democratizing access to high-value proteomic data [19][24] - The planned launch of the Nautilus Proteome Analysis Platform, instruments, reagents, and software is set for mid-2024, with ongoing investments in scientific progress [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term impact of their innovation and the potential to expand the proteomics market [5] - The company anticipates an increase in cash burn but expects its cash runway to extend well into 2025, allowing for continued focus on scientific progress [13][27] Other Important Information - The company added 5 new patent applications and was granted 4 new U.S. patents in Q1, raising the total to 12 granted U.S. patents [22] - The First Access Challenge received a positive response from researchers, indicating strong interest in the platform [8][25] Q&A Session Summary Question: How do you anticipate each of these projects will specifically highlight and demonstrate the differentiated capabilities in the Nautilus platform? - Management highlighted the diversity of questions being asked across different medical domains and the unique materials being studied, showcasing the platform's sensitivity and dynamic range [51][52] Question: What is the status of the Early Access program and its key deliverables? - The Early Access program is designed to allow customers to test the technology ahead of the commercial launch, with a focus on generating valuable data and driving preorders [58][60] Question: How does the company view the clinical market's receptiveness to multi-analyte proteomics? - The company plans to focus on the research-only market in the medium term, with potential future involvement in clinical applications as the technology matures [55] Question: What is the expected pace of the commercial launch in 2024? - Management did not provide specific revenue guidance but indicated that the launch would be strategically paced, leveraging existing customer interest and market demand [62] Question: How is the supplier base for reagents and instruments being managed? - The company has established relationships with multiple suppliers to mitigate risks and ensure quality in both instrument assembly and consumable production [69]

Financial Data and Key Metrics Changes - For fiscal year 2022, operating expenses increased to $63.6 million from $50.5 million in 2021, representing a 26% increase driven by personnel costs and expenses related to operating as a public company [1] - The net loss for the full year was $57.9 million, up from $50.3 million in fiscal year 2021, marking a 15% year-over-year increase [2] - Total operating expenses for Q4 2022 were $16.3 million, which was $500,000 less than the same quarter last year, indicating a focus on controlling spending while investing in growth [33] Business Line Data and Key Metrics Changes - Research and development expenses in Q4 2022 were $9.6 million compared to $9.9 million in the prior year, while general and administrative expenses were $6.7 million, down from $6.9 million [34] - The company anticipates overall operating expenses to grow by approximately 40% from 2022 levels in 2023, while managing spending tightly to preserve investment capabilities [3] Market Data and Key Metrics Changes - The company ended the year with approximately $314 million in cash, cash equivalents, and investments, representing a trailing 12-month cash burn of approximately $48.5 million, with expectations for the cash runway to extend well into 2025 [5] Company Strategy and Development Direction - The company aims to revolutionize proteomics and positively impact health and lives globally, with a focus on commercial expansion leading up to a platform launch in mid-2024 [8][4] - The Nautilus First Access Challenge was announced to inspire researchers and unlock creativity in exploring biological insights, indicating a commitment to engaging the scientific community [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage resources effectively amid challenging financial conditions, with a focus on maximizing runway and balancing investments for scientific progress [32] - The management team believes that the product being developed has a strong value proposition and a wide competitive moat, with no significant competitive advancements observed in the proteomics space [96][97] Other Important Information - The company nearly doubled its patent portfolio to over 40 pending patent families filed in the U.S. and abroad, with a total of 11 granted U.S. patents [30] - The company is focused on building a commercial team closer to the launch date, reflecting a cautious approach to scaling operations in the current economic environment [76] Q&A Session Summary Question: Has the company's appetite for M&A changed recently? - Management indicated that while the M&A environment has picked up, there are no near-term plans for M&A, focusing instead on leveraging the balance sheet for platform development [42][55] Question: What advancements should be expected in the near term? - Management highlighted the importance of scientific conferences and continued data sharing with the scientific community as key indicators of progress towards the commercial launch [43][44] Question: What feedback has been received from the scientific community? - Positive feedback was noted regarding the platform's sensitivity, scale, and potential to complement existing mass spectrometry methods, with researchers expressing excitement about the capabilities [45][46] Question: What are the key features the clinical market will look for? - The management believes that the transition from single biomarker assays to broader protein panels will occur naturally, driven by the need for comprehensive analysis in clinical settings [98][99]

Business Combination and Financial Overview - Nautilus Biotechnology completed a business combination on June 9, 2021, resulting in the issuance of 20,000,000 shares at $10.00 per share, raising gross proceeds of $200 million[26]. - The company incurred net losses of $57.9 million and $50.3 million for the years ended December 31, 2022 and 2021, respectively, with an accumulated deficit of $138.6 million as of December 31, 2022[217]. - The Nautilus platform remains in the development stage, and the company has not yet commercialized any products, expecting to continue incurring significant losses[203]. - The company anticipates beginning meaningful early access engagements and associated revenue at the start of 2024, leading to broader commercialization in mid-2024[220]. - The company may need to raise additional capital to fund its development and commercialization plans[206]. Market Potential and Growth - The proteomics market is estimated to be approximately $27 billion in annual spending as of 2022, with expectations to reach $55 billion by 2027, representing a CAGR of 15%[32]. - The global proteomics market was valued at approximately $27 billion in 2022 and is projected to reach around $55 billion by 2027, representing a CAGR of 15% over the five-year period[57]. - The proteomics market is expected to evolve with substantial adjacent opportunities in clinical diagnostics and machine-learning powered drug discovery[58]. - The proteomics research marketplace is estimated to have over 16,000 installed mass spectrometry systems, indicating a strong demand for protein data in biology and drug development[61]. Technology and Innovation - Nautilus aims to develop a proteome analysis system capable of identifying approximately 95% of proteins in a sample, significantly enhancing the ability to characterize the proteome[31]. - The Nautilus platform is designed to generate up to approximately 20 terabytes of digital protein data per run, utilizing proprietary machine learning algorithms for data analysis[37]. - The Nautilus platform aims to provide a comprehensive proteomics solution, combining instruments, consumables, and software to unlock valuable biological information[37]. - The Nautilus platform aims to achieve extreme sensitivity and scale by measuring billions of individual protein molecules simultaneously, utilizing a unique architecture and advanced machine learning software[65][76]. - The platform is designed to cover a very large dynamic range, enabling the detection of proteins present in quantities ranging from a few to hundreds of millions of molecules[76]. - The platform's multi-cycle optical and fluidics instrument enables repeated probing of captured proteins, allowing for deeper characterization and decoding of the whole proteome[81]. - The Nautilus platform employs a novel class of multi-affinity probe reagents, estimated to achieve detection of the vast majority of proteins in the proteome using approximately 300 unique probes[87]. - The machine learning protein identification analysis processes data for each of the 10 billion protein molecules captured on the flow cell in parallel, enabling cumulative absolute quantification[95]. - The platform aims to create matched DNA, RNA, and protein datasets for integrated multi-omic analyses, enhancing understanding of gene-to-protein information transfer[129]. Commercial Strategy and Partnerships - The company has established partnerships with key biopharma companies and academic institutions, including Genentech and Amgen, to validate its technology and applications[33]. - Nautilus plans to launch an early access program for an expanded group of customers, which will serve as reference sites to aid in market adoption[33]. - The company plans to drive adoption of the Nautilus platform through a three-phase commercial strategy, starting with partnerships and collaborations with biopharma companies and academic institutions[9]. - The commercial strategy includes direct sales of the Nautilus platform, ongoing consumables sales, and a SaaS analytics subscription, creating a compelling value proposition across multiple market segments[147]. - A formal partnering program has been initiated to establish multiple research collaborations, generating data and publications in high-impact research areas[155]. Regulatory and Compliance Challenges - The company may face increased regulation from the FDA for products intended for disease diagnosis, which could impact development and marketing[170]. - The FDA classifies medical devices into three classes, with class III devices requiring premarket approval (PMA) that can take one to two years[172]. - Obtaining regulatory approvals can be expensive and time-consuming, potentially delaying product launches and commercialization[173]. - The company currently labels products for research purposes only, but regulatory uncertainties could adversely affect business operations if products are deemed subject to FDA clearance[174]. - International sales of medical devices will be subject to varying foreign regulations, including the EU's IVD Medical Device Regulation (IVDR) effective May 26, 2022[176]. Intellectual Property and Competitive Landscape - The company has built a strong intellectual property portfolio since its inception in 2016, securing numerous key patents[35]. - The company holds eight issued U.S. patents and approximately fifty-five pending foreign patent applications, with expiration expected between 2037 and 2043[187]. - The competitive landscape includes established companies like Agilent Technologies and Thermo Fisher Scientific, but the company believes its unique technology offers significant differentiation[164]. Workforce and Organizational Structure - The company employs a highly interdisciplinary team of approximately 134 employees, with 51 holding a Ph.D., driving its scientific and technological advancements[35]. - As of December 31, 2022, the company had 134 employees, with 95 engaged in research and development activities[197].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-15 ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - CFO Conference Call Participants Max Masucci - Cowen David Delahunt - Goldman Sachs Brandon Couillard - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Nautilus Q3 2022 Earnings Call. [Operator Instructions] I would now like to turn the call over to your ...

PART I. FINANCIAL INFORMATION This section presents Nautilus Biotechnology, Inc.'s unaudited condensed consolidated financial statements and management's analysis [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows, with detailed explanatory notes [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheets show a decrease in total assets and stockholders' equity from December 31, 2021, to June 30, 2022, primarily due to a reduction in short-term investments and an increase in accumulated deficit Condensed Consolidated Balance Sheets (in thousands) | Metric | June 30, 2022 (in thousands) | Dec 31, 2021 (in thousands) | Change ($) | | :--------------------------- | :--------------------------- | :-------------------------- | :--------- | | Total Assets | $371,707 | $398,450 | $(26,743) | | Total Liabilities | $34,149 | $34,874 | $(725) | | Total Stockholders' Equity | $337,558 | $363,576 | $(26,018) | | Accumulated Deficit | $(111,092) | $(80,640) | $(30,452) | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The statements of operations reveal increased operating expenses and a larger net loss for both the three and six months ended June 30, 2022, compared to the same periods in 2021 Net Loss (Three and Six Months Ended June 30) (in thousands) | Metric | Three Months Ended June 30, 2022 (in thousands) | Three Months Ended June 30, 2021 (in thousands) | Six Months Ended June 30, 2022 (in thousands) | Six Months Ended June 30, 2021 (in thousands) | | :------------------------------------------------- | :---------------------------------------------- | :---------------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Net Loss | $(14,689) | $(10,713) | $(30,452) | $(19,122) | - Research and development expenses increased by **$7.3 million (65%)** for the six months ended June 30, 2022, primarily due to higher salaries, benefits, stock-based compensation, development services, and facilities costs[23](index=23&type=chunk)[137](index=137&type=chunk) - General and administrative expenses increased by **$5.1 million (64%)** for the six months ended June 30, 2022, mainly due to increased salaries, benefits, stock-based compensation, insurance, and facilities costs[23](index=23&type=chunk)[138](index=138&type=chunk) [Condensed Consolidated Statements of Comprehensive Loss](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) The comprehensive loss increased for both the three and six months ended June 30, 2022, compared to 2021, reflecting the higher net loss and a notable increase in unrealized losses on available-for-sale securities Comprehensive Loss (Three and Six Months Ended June 30) (in thousands) | Metric | Three Months Ended June 30, 2022 (in thousands) | Three Months Ended June 30, 2021 (in thousands) | Six Months Ended June 30, 2022 (in thousands) | Six Months Ended June 30, 2021 (in thousands) | | :----------------- | :---------------------------------------------- | :---------------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Comprehensive Loss | $(14,903) | $(10,725) | $(31,036) | $(19,135) | - Unrealized loss on securities available-for-sale increased from **$(13) thousand** in 2021 to **$(584) thousand** in 2022 for the six-month period[25](index=25&type=chunk) [Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Redeemable%20Convertible%20Preferred%20Stock%20and%20Stockholders%27%20Equity) This statement shows that all redeemable convertible preferred stock was converted to common stock in June 2021, resulting in no preferred stock outstanding as of June 30, 2022 Stockholders' Equity and Accumulated Deficit (in thousands) | Metric | June 30, 2022 (in thousands) | Dec 31, 2021 (in thousands) | | :------------------------- | :--------------------------- | :-------------------------- | | Total Stockholders' Equity | $337,558 | $363,576 | | Accumulated Deficit | $(111,092) | $(80,640) | - Stock-based compensation expense for the six months ended June 30, 2022, was **$4,677 thousand**, an increase from **$3,156 thousand** in the prior year[28](index=28&type=chunk)[91](index=91&type=chunk) - As of June 30, 2022, **124,562,745 shares** of common stock were issued and outstanding[27](index=27&type=chunk)[28](index=28&type=chunk)[78](index=78&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2022, net cash provided by investing activities significantly increased, while net cash provided by financing activities sharply decreased compared to 2021 Cash Flow Summary (Six Months Ended June 30) (in thousands) | Cash Flow Activity | 2022 (in thousands) | 2021 (in thousands) | Change ($) | | :---------------------------------------- | :------------------ | :------------------ | :--------- | | Net cash used in operating activities | $(25,864) | $(14,545) | $(11,319) | | Net cash provided by (used in) investing activities | $50,258 | $(61,048) | $111,306 | | Net cash provided by financing activities | $341 | $327,373 | $(327,032) | | Net increase in cash, cash equivalents and restricted cash | $24,735 | $251,780 | $(227,045) | - Cash, cash equivalents and restricted cash at the end of the period was **$211,196 thousand** as of June 30, 2022[30](index=30&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes provide comprehensive details on business, accounting policies, recapitalization, fair value, equity, income tax, stock compensation, and commitments [1. Description of Business and Basis of Presentation](index=12&type=section&id=1.%20Description%20of%20Business%20and%20Basis%20of%20Presentation) Nautilus is a development-stage biotechnology company focused on its proteomics platform, with significant capital raised but an accumulated deficit and ongoing COVID-19 impacts - Nautilus Biotechnology, Inc. is a development-stage company incorporated in 2016, focused on research and development of its proteomics platform[31](index=31&type=chunk)[110](index=110&type=chunk) - The company consummated a Business Combination (reverse recapitalization) and PIPE Financing on June 9, 2021, raising approximately **$345.5 million** in gross proceeds[32](index=32&type=chunk)[33](index=33&type=chunk)[115](index=115&type=chunk) - As of June 30, 2022, the company had an accumulated deficit of **$111.1 million** and cash, cash equivalents, and short-term investments of **$299.3 million**, which are expected to fund operations for the next 12 months[36](index=36&type=chunk)[37](index=37&type=chunk)[115](index=115&type=chunk) - The COVID-19 pandemic has led to supply disruptions (e.g., extended chip lead times, diverted lab materials, lower reagent availability) and economic volatility, with its full impact on the business remaining unpredictable[39](index=39&type=chunk)[119](index=119&type=chunk) [2. Significant Accounting Policies](index=13&type=section&id=2.%20Significant%20Accounting%20Policies) This section details significant accounting policies, including estimates, credit risk, segment reporting, investments, leases, and comprehensive loss, noting no material impact from recent pronouncements - The preparation of financial statements requires management to make significant estimates and assumptions, which are evaluated on an ongoing basis[41](index=41&type=chunk)[42](index=42&type=chunk) - The company relies on single-source suppliers for certain components, reagents, and antibodies used in its Nautilus platform, posing concentration of credit risk[44](index=44&type=chunk) - Nautilus operates in one operating and one reportable segment, with all long-lived assets located in the United States[46](index=46&type=chunk) - Investments are classified as available-for-sale and reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss)[49](index=49&type=chunk) - The company adopted ASU 2020-04 (Reference Rate Reform) effective January 1, 2022, with no material impact on its financial statements, and does not anticipate a material impact from ASU 2016-13 (Credit Losses) and ASU 2019-12 (Income Taxes) upon future adoption[59](index=

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Sujal Patel - Founder and Chief Executive Officer Anna Mowry - Chief Financial Officer Parag Mallick - Founder and Chief Scientist Conference Call Participants Stephanie Yan - Cowen and Company, LLC Tejas Savant - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2022 Earnings Conference Call. At th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR Delaware 98-1541723 (State or other jurisdiction of incorporation or organization) 2701 Eastlake Avenue East Seattle, Washington 98102 (Address of principal executive offices) (Zip Code) (206) 333-2001 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Financial Data and Key Metrics Changes - Total operating expenses for Q1 2022 were $16.0 million, a 90% increase from $8.4 million in Q1 2021, primarily due to increased headcount and costs associated with being a public company [16][17] - Research and development expenses for Q1 2022 were $9.7 million, compared to $4.8 million in Q1 2021 [17] - General and administrative expenses for Q1 2022 were $6.4 million, compared to $3.6 million in Q1 2021 [17] - Overall net loss for Q1 2022 was $15.8 million, compared to $8.4 million in Q1 2021 [17] - The company ended the quarter with approximately $349 million in cash, cash equivalents, and investments, providing a strong cash runway through commercialization [18] Business Line Data and Key Metrics Changes - The company reported solid progress against scientific goals and maturation of development processes for consumables and instruments [10] - Significant attention was received for the collaboration results with Genentech, indicating strong interest in the company's technology [10][11] Market Data and Key Metrics Changes - The company noted increased engagement with the scientific community and potential customers, indicating growing interest in new proteomics approaches [30] - The investment community has become more informed about the proteomics market, with increased interest in the company's offerings [29] Company Strategy and Development Direction - Nautilus aims to revolutionize biomedical research by unlocking the potential of the proteome, focusing on target identification and therapeutic development [6][9] - The company is committed to scaling up a world-class team and maintaining a high-performance culture to support its long-term mission [8] - The upcoming Analyst Day in September will include a preview of the planned pricing model and public unveiling of instruments [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate supply chain challenges and maintain progress towards commercialization [26] - The company remains focused on scientific advancements and plans to provide updates through publications and presentations at conferences [49] Other Important Information - The appointment of Gwen Weld as Chief People Officer is expected to enhance the company's culture and collaborative environment [8] - The company is actively working on partnerships with Amgen and MD Anderson, although specific details on progress remain limited [48] Q&A Session Summary Question: Supply chain diversification benefits - Management confirmed ongoing efforts to diversify suppliers and manage single-source component supply effectively, with no significant impact on progress [25][26] Question: Evolving conversations in the proteomics market - Management noted increased awareness and interest from investors and the scientific community regarding proteomics, leading to more informed discussions [29][30] Question: Operating expenses and headcount expectations - Management expects operating expenses to grow, driven by headcount increases, with a positive outlook on the ability to grow the team [33] Question: Key learnings from the Genentech collaboration - The collaboration highlighted the importance of proteoforms and the need for efficient onboarding of commercially available content [37] Question: Update on partnerships with Amgen and MD Anderson - Management stated it is still early to share detailed information about these partnerships, but progress is being made [48] Question: Tracking progress towards launch - Management advised investors to look for data updates through publications and presentations as the company moves towards commercialization [49]

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2021 were $16.8 million, up from $5.3 million in Q4 2020, primarily due to scaling the team to a headcount of 113, roughly doubling year-over-year [31] - Research and development expenses for Q4 2021 were $9.9 million compared to $3.9 million in Q4 2020, driven by increased personnel costs and development pipeline scaling [31] - Net loss for Q4 2021 was $16.7 million, compared to $5.4 million in Q4 2020 [32] - The company ended the year with approximately $362 million in cash, cash equivalents, and investments [33] Business Line Data and Key Metrics Changes - The company is focused on developing its proteomics platform, which aims to democratize access to proteomics and improve drug discovery and diagnostics [10][12] - Significant progress has been made in R&D, with a focus on consumables and instruments, including a reduction in reagent creation time by a factor of 10 and an increase in yield by a factor of 2 [15] Market Data and Key Metrics Changes - The proteomics market is estimated to be approximately $25 billion, growing at a 12% CAGR [9] - The company anticipates reaching comprehensive coverage of the human proteome by mid-2023 and a commercial launch by the end of 2023 [22] Company Strategy and Development Direction - The company aims to revolutionize biological science by providing accessible proteomics technologies that can accelerate target identification and drug development [10][12] - Nautilus is building strategic partnerships to diversify its supply chain and enhance its probe development capabilities [17][27] - The company is focused on expanding its intellectual property portfolio, having recently been awarded its fourth U.S. patent [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving commercial launch timelines despite some delays in probe development and characterization processes [49][50] - The company is optimistic about the market's excitement for single molecule protein analysis methods and believes it can outperform existing methods [20][29] - Management highlighted the competitive landscape, noting that Nautilus offers significant advantages in sensitivity and dynamic range compared to mass spectrometry and peptide sequencing methods [61][64] Other Important Information - The company plans to host its inaugural Analyst Day in late September to discuss its pricing model and market analysis [35] - The management team emphasized the importance of early customer engagement and the need for ongoing investments in R&D and commercial activities [33][36] Q&A Session Summary Question: What is the current headcount compared to Q3 and any key roles still looking to add? - The company ended the year at 113, doubling year-over-year, and plans to continue investing in R&D and commercial teams [38][39] Question: Clarification on the Genentech collaboration update? - The company will present work from the Genentech collaboration at the US HUPO meeting [41] Question: Updates on MD Anderson-Amgen partnerships? - The agreements were recently signed, and the company is in the early stages of understanding the biological questions to address [42] Question: Details on agreements with three new partners? - The new partners are focused on increasing probe development strategies and complementing existing agreements [44] Question: Drivers of the compressed probe schedule? - The company is behind schedule but remains confident in achieving its milestones due to scaled-up internal and external efforts [48][49] Question: Value addition in the clinical diagnostics market? - The company sees the need for research use partners to lay the foundation for downstream clinical applications, particularly in orphan diseases [58] Question: Positioning versus competitors in protein sequencing? - Nautilus provides significant advantages in coverage, sensitivity, and dynamic range compared to mass spectrometry and peptide sequencing methods [60][61] Question: Impact of wage and cost input inflation? - The company is experiencing competitive labor costs and supply chain challenges but is prioritizing spending to meet objectives [65]